CybernaX Biotechnologies
Platforms

Two lipid platformsfor next generation non-viral delivery.

Platform 01 ELITE — Embodied Lipid Intelligence for Targeted Expression

CX Ionizable Lipid

Embodied AI lipid screening = AI foundation model + empirical chemistry design + automated wet lab + in vitro / in vivo validation

The combination that balances high cellular uptake and high endosomal escape with the fast degradation that keeps toxicity low.

For advanced research, we screen for tissue distribution, tailored formulation and your specific delivery need.

For programs already underway, we have five NHP-validated lipids that fall into three clusters:

  • Gene editing and in vivo CAR applications
  • Protein replacement for long-term dosing
  • Vaccine and adjuvant use
  • Embodied AI enabled lipid screening
  • CMC ready lipid for scale-up synthesis
  • NHP validated lipids for a variety of applications
Backbone conformational response and endosomal escape Two CX lipid backbones compared. In the left design the angle between the lipid tails barely changes between a polar and an apolar environment, and the endosomal membrane stays intact, so the payload is retained. In the right design the backbone opens much further in the apolar environment, destabilising the membrane so the payload reaches the cytosol. Limited endosomal escape Enhanced endosomal escape POLAR ENVIRONMENT N N small conformational change large conformational change APOLAR ENVIRONMENT N N payload retained in the endosome payload released to the cytosol

Schematic representation; not to scale.

Platform 02 ENDURE — Engineered Non-immunogenic Defined, Uniform lipid for Repeat Exposure

CX Stabilizing Lipid

Low-immunogenicity stabilizing lipid — stable liposomes and LNPs that support long-term, multiple dosing.

Anti-PEG antibodies are present in a meaningful fraction of treatment-naive people, and dosing induces more. What makes them a particular problem for LNPs is architecture rather than chemistry: an LNP presents PEG as a dense, laterally mobile array of PEG-lipids across its surface, where a PEGylated protein carries one or a few chains on a single molecule. That polyvalent surface lets anti-PEG IgM and IgG cross-link into large immune complexes and engage the classical complement pathway efficiently — which single-chain PEGylated proteins largely do not.

Complement activation drives accelerated blood clearance and complement activation-related pseudoallergy, and it attacks the carrier itself: opsonised particles lose bilayer integrity and can release their payload into serum before reaching the target cell.

Replacing the PEG-lipid with our stabilizing lipid removes that liability at the source. It is a defined molecule with a monodispersed polymer design, so both the IP position and the CMC specification stay unambiguous.

  • Defined molecular weight
  • Low immunogenicity
  • Stable expression across repeat dosing
hEPO expression across repeat doses Relative expression 1st dose5th dose 1st dose5th dose LNP with PEG-Lipids LNP with CX Stabilizing Lipid

Figures are illustrative only. Full data will be shared following execution of a CDA.

Overcoming critical barriers

Three barriers in nucleic acid delivery — and how we clear them.

Barrier 01

Low efficacy from endosomal entrapment

More than 98% of delivered RNA stays trapped in the endosome and is degraded before it can act.

CybernaX solution

AI-screened lipid backbones. An iterative foundation model with in vitro and in vivo verified data identifies backbones with markedly enhanced endosomal release — confirmed in NHP.

Barrier 02

High-efficacy designs cause toxicity

Conventional high-potency lipids are poorly tolerated, which caps the dose level a program can reach.

CybernaX solution

Biodegradable tails by design. Lipids clear rapidly after delivery rather than accumulating — widening the therapeutic window and lifting the ceiling on dose.

Barrier 03

Extrahepatic delivery and cell targeting

ApoE adsorbs onto the particle after administration and routes it to the liver, leaving extrahepatic targets hard to reach.

CybernaX solution

A dual strategy. Formulation modification to reduce liver tropism, combined with active ligand-mediated targeting for cell-specific delivery.

Multiple patent families filed — now entering the national phase

Our ionizable lipid backbones, formulation approaches and stabilizing lipid chemistry are covered by several patent applications that are progressing into national phase across key jurisdictions.

Freedom-to-operate reviewed continuously — no infringement identified

We run FTO analysis on an ongoing basis as the landscape moves, not once at filing. To date no infringement has been found for the chemistries we license.

Partnering with us

Tell us your target tissue, payload and mechanism of action. We will tell you which lipid chemistry gets you there.

info@cybernaxbio.com